SciSparc (SPRC) - הכנסות ממכירות החברה

SciSparc Ltd relies on external contractors for synthesis and testing, operating in a pre-commercial mode with a linear burn rate. The company's annual sales volume clearly demonstrates the asset's liquidity, while 0.00 indicates the current level of the metric. The business focuses on creating unique cannabinoid formulas for the therapy of Alzheimer's disease and Tourette syndrome.

For the long-term investor, the stability of SciSparc Ltd (SPRC) is determined by its ability to monetize cannabinoid-based drug developments through clinical trials. When analyzing the company's sales trend, it should be noted that this indicator captures the daily consolidation of all commercial operations, reflecting real demand for innovative therapies for disorders and pain syndromes, which allows for an assessment of business resilience excluding temporary market anomalies.